IP Library Patent Application 17037070
Patent Application
App. No. 17/037,070

COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/037,070
Abstract

The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.

Claims (51)

1 . (canceled)

2 . A method of treating rosacea, comprising administrating a foam composition comprising:

a) a combination of at least one fatty alcohol and at least one wax; or a combination of at least one fatty alcohol, at least one fatty acid, and at least one wax;

b) at least one hydrophobic solvent; and

c) a minocycline at a concentration between about 0.2% and about 20% by weight of the composition;

wherein the composition is free of surfactant;

wherein the composition has a water activity (Aw) value of less than about 0.9; and

wherein the ratio of (1) fatty alcohol to wax or (2) fatty alcohol and fatty acid to wax is between about 1:3 and about 3:1.

3 . The method of claim 2 , wherein the minocycline is present in a free base form, a hydrate form, a salt form, or a complex form.

4 . The method of claim 2 , wherein the foam composition further comprises a doxycycline.

5 . The method of claim 2 , wherein the concentration of the minocycline is between about 1% and about 4% by weight of the composition.

6 . The method of claim 2 , wherein the concentration of the minocycline is about 1.5% by weight of the composition.

7 . The method of claim 2 , wherein the at least one fatty alcohol comprises 14 carbon atoms in its backbone.

8 . The method of claim 2 , wherein the fatty alcohol comprises stearyl alcohol, cetostearyl alcohol, behenyl alcohol, and/or myristyl alcohol.

9 . The method of claim 2 , wherein the at least one fatty alcohol is present at a concentration from about 0.1% to about 20% by weight of the composition.

10 . The method of claim 2 , wherein the at least one wax and/or the at least one fatty acid is present at a concentration from about 0.1% to about 20% by weight of the composition.

11 . The method of claim 2 , wherein the hydrophobic solvent comprises soybean oil, coconut oil, cyclomethicone, and/or mineral oil.

12 . The method of claim 2 , wherein the hydrophobic solvent is present at a concentration from about 60% to about 95% by weight of the composition.

13 . The method of claim 2 , wherein the foam composition further comprises a silicon dioxide.

14 . The method of claim 2 , wherein the wax comprises beeswax and/or hydrogenated castor oil.

15 . The method of claim 2 , wherein the wax comprises beeswax and hydrogenated castor oil.

16 . The method of claim 15 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 5:1 to about 1:1.

17 . The method of claim 15 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 2:1 to about 1:1.

18 . The method of claim 15 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 4:3.

19 . The method of claim 15 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 1:1.

20 . The method of claim 2 , wherein the composition has an Aw value of less than about 0.5.

21 . A method of treating rosacea, comprising administrating a foam composition comprising:

a) a combination of at least one fatty alcohol and at least one wax; or a combination of at least one fatty alcohol, at least one fatty acid, and at least one wax;

b) at least one hydrophobic solvent; and

c) a minocycline at a concentration between about 0.2% and about 20% by weight of the composition;

wherein the composition is free of surfactant;

wherein the composition is essentially waterless; and

wherein the ratio of (1) fatty alcohol to wax or (2) fatty alcohol and fatty acid to wax is between about 1:3 and about 3:1.

22 . The method of claim 21 , wherein the minocycline is present in a free base form, a hydrate form, a salt form, or a complex form.

23 . The method of claim 21 , wherein the foam composition further comprises a doxycycline.

24 . The method of claim 21 , wherein the concentration of the minocycline is between about 1% and about 4% by weight of the composition.

25 . The method of claim 21 , wherein the concentration of the minocycline is about 1.5% by weight of the composition.

26 . The method of claim 21 , wherein the at least one fatty alcohol comprises 14 carbon atoms in its backbone.

27 . The method of claim 21 , wherein the fatty alcohol comprises stearyl alcohol, cetostearyl alcohol, behenyl alcohol, and/or myristyl alcohol.

28 . The method of claim 21 , wherein the at least one fatty alcohol is present at a concentration from about 0.1% to about 20% by weight of the composition.

29 . The method of claim 21 , wherein the at least one wax and/or the at least one fatty acid is present at a concentration from about 0.1% to about 20% by weight of the composition.

30 . The method of claim 21 , wherein the hydrophobic solvent comprises soybean oil, coconut oil, cyclomethicone, and/or mineral oil.

31 . The method of claim 21 , wherein the hydrophobic solvent is present at a concentration from about 60% to about 95% by weight of the composition.

32 . The method of claim 21 , wherein the foam composition further comprises a silicon dioxide.

33 . The method of claim 21 , wherein the wax comprises a mixture of beeswax and/or hydrogenated castor oil.

34 . The method of claim 21 , wherein the wax comprises beeswax and hydrogenated castor oil.

35 . The method of claim 34 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 5:1 to about 1:1.

36 . The method of claim 34 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 2:1 to about 1:1.

37 . The method of claim 34 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 4:3.

38 . The method of claim 34 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 1:1.

39 . The method of claim 21 , wherein the composition has an Aw value of less than about 0.5.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2022
From: VYNE THERAPEUTICS INC.; VYNE PHARMACEUTICALS INC.
To: JOURNEY MEDICAL CORPORATION
Reel/Frame 058925/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2021
From: VYNE THERAPEUTICS INC.
To: VYNE PHARMACEUTICALS INC.
Reel/Frame 058463/0208 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0708 →
PATENT SECURITY AGREEMENT Recorded Feb 17, 2021
From: VYNE THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 055326/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: VYNE PHARMACEUTICALS LTD.
To: VYNE THERAPEUTICS INC.
Reel/Frame 055215/0298 →
CHANGE OF NAME Recorded Nov 4, 2020
From: FOAMIX PHARMACEUTICALS LTD.
To: VYNE PHARMACEUTICALS LTD.
Reel/Frame 054306/0387 →
CHANGE OF NAME Recorded Sep 30, 2020
From: FOAMIX LTD.
To: FOAMIX PHARMACEUTICALS LTD.
Reel/Frame 053933/0020 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2020
From: TAMARKIN, DOV; GAZAL, ELANA; HAZOT, YOHAN; SCHUZ, DAVID; PAPIASHVILI, IRAKLIY
To: FOAMIX LTD.
Reel/Frame 053929/0522 →